compared lung adenocarcinoma TMB data of TP53-missense-mutant and TP53-nonsense-mutant groups to TP53-wild-type groups from Memorial Sloan Kettering Cancer Center (MSKCC) (p < 0.01 and p < 0.05 respectively), TCGA (p < 0.0001 for both) and GENE + (p < 0.0001 for both) databases using a Wilcoxon test and reported that both TP53-mutant groups demonstrated elevated TMB and neoantigen levels compared to the TP53-wild-type group [42]. Here, TP53 is linked to lung adenocarcinoma.